García-Carrancá A

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 437-442
Archivo PDF: 83.01 Kb.

RESUMEN

Actualmente, las infecciones “persistentes” por algunos tipos del virus del papiloma humano se consideran como necesarias para desarrollar cáncer cervicouterino. Por ello, el desarrollo de vacunas eficientes contra estos virus se ha considerado de suma importancia para poder eventualmente ayudar a controlar esta enfermedad, en países donde los programas de detección oportuna no han dado aún los resultados deseados. En el caso de estos virus no es posible el desarrollo de vacunas tradicionales, las cuales están basadas generalmente en el empleo de virus atenuados o muertos. Esto debido a la falta de sistemas eficientes para producir partículas virales en cantidades suficientes para ser usadas en programas masivos. Sin embargo, de manera afortunada, la expresión de la proteína viral tardía L1, sola o en combinación con la proteína L2, lleva a la generación de estructuras similares a los viriones infectivos y que han sido denominadas “partículas semejantes a virus” o VLP. Estas preparaciones de cápsides vacías han sido probadas ya en diferentes modelos animales, incluidos los humanos. Recientemente, se ha reportado que la las VLP del virus del papiloma humano tipo 16 son capaces de prevenir el desarrollo de las infecciones “persistentes” causadas por algunos tipos del virus del papiloma humano, consideradas precursoras del cáncer cervicouterino.

REFERENCIAS (EN ESTE ARTÍCULO)

1. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2002. 2:342-350.

2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999. 189:12-19.

3. Frazer IH. Vaccines for papillomavirus infection. Virus Res. 2002. 89:271-274.

4. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles . Virology. 1991. 185:251-257.

5. Ault KA. Virus-like particles as a potential vaccine for human papillomavirus. Papillomavirus Rep. 2003;14:47-51.

6. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995. 92:11553-11557.

7. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh- Desmarquet C et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-3963.

8. Kirnbauer R, Chandrachud LM, O’Neil BW, Wagner ER, Grindlay GJ, Armstrong A et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996. 219:37-44.

9. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particule vaccine. J Natl Cancer Inst 2001; 93:284-292.

10. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Immunological analyses of human papillomavirus capsids. Vaccine 2001;19:1783-93.

11. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al. A Phase 1 study of a recombinant viruslike particule vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183:1485-1493.

12. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.

13. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77:1551-1563.

14. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-1527.

15. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-3416.

16. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 1998. 4:2103-2109.

17. de Jong A, O’Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-3464 .

18. van der Burg SH, Kwappenberg KM, O’Neill T, Brandt RM, Melief CJ, Hickling JK et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001;19:3652-3660.

19. Mendoza L, BubenikJ, Simova J, Jandlova T, Vonka V, Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 2003;23:243-247.

20. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J et al. Chimeric papillomavirus-like particles. Virology 1997;234:93-111.

21. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Muller M et al. Chimeric papillomavirus virus-like particles induce a murine selfantigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 1999;73:145-152.

22. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003;21:3219-3227.

23. Berumen J, Casas L, Segura E, Amezcua JL, García-Carrancá A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int J Cancer 1994; 56:640-645.

24. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis.EMBO J. 1997. 16:504-514.

25. Demeret C, García-Carrancá A, Thierry F. Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 2003;22:168-175.

26. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.

27. Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology 2000;43:331-338.

28. Rocha-Zavaleta L, Alejandre J, García-Carrancá A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 2002;66:86-95.

29. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002;89:285-293.